Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Divaka Perera (King’s College London & Guy’s & St Thomas’ Hospital, UK) and investigator, Dr Peter O'Kane (Royal Bournemouth Hospital, UK) to discuss the REVIVED-BCIS2 viability analysis (NCT01920048).

This analysis of the REVIVED-BICS2 trial found that viability characterisation does not impact the effect of PCI on prognosis or LV recovery in ischaemic cardiomyopathy, compared to optimised guideline therapy (OMT) alone. The study also showed that scar burden can predict prognosis and the likelihood of LV recovery in ischaemic cardiomyopathy independent of baseline LVEF or extent of CAD.

Recorded remotely from Hamilton, London and Dorset, 2023.
Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "ACC 23 Late-Breaker Discussion: The REVIVED-BCIS2 Viability Study" передвинте ползунок вправо